Journal
CANCER TREATMENT REVIEWS
Volume 37, Issue 1, Pages 63-74Publisher
ELSEVIER SCI LTD
DOI: 10.1016/j.ctrv.2010.05.001
Keywords
Tumor-Vascular Disrupting Agents; Tumor-VDAs; ASA404; Tubulin-binding agents; CA4P; Tumor vasculature; Anti-vascular therapy
Categories
Funding
- National Cancer institute [R01 CA084408]
- Novartis Pharmaceuticals Corporation
Ask authors/readers for more resources
The vasculature of solid tumors is fundamentally different from that of normal vasculature and offers a unique target :for anti-cancer therapy. Direct vascular-targeting with Tumor-Vascular Disrupting Agents (Tumor-VDAs) is distinctly different from anti-angiogenic strategies, and offers a complementary approach to standard therapies. Tumor-VDAs therefore have significant potential when combined with chemotherapy, radiotherapy, and angiogenesis-inhibiting agents. Preclinical studies with the different Tumor-VDA classes have demonstrated key tumor-selective anti-vascular and anti-tumor effects. (C) 2010 Elsevier Ltd. All rights reserved.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available